GFA
RARE icon

Godfrey Financial Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Godfrey Financial Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267 Hold
8
– – ﹤0.01% 974
2026
Q1 		$168 Hold
8
– – ﹤0.01% 1027
2025
Q4 		$184 Buy
+8
New +$263 ﹤0.01% 993

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Godfrey Financial Associates's RARE Position: Q2 2026 in Review

Godfrey Financial Associates held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 8 shares worth $267. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Godfrey Financial Associates first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Godfrey Financial Associates held 8 shares of Ultragenyx Pharmaceutical worth $267 as of Q2 2026.
  • Godfrey Financial Associates left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Godfrey Financial Associates's portfolio in Q2 2026, its #974 holding.
  • Godfrey Financial Associates first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Godfrey Financial Associates's 13F filing for Q2 2026, filed 11 Aug 2026.